


NASPCC Webinar Series Presents:
“State of Play of Radiopharmaceuticals”

with Michael Morris, MD

Wednesday, January 22, 2025

7:00 pm EASTERN / 4:00 pm PACIFIC

To register for this event, please click [here](#) or visit the NASPCC website at www.NASPCC.org



Dr. Michael Morris is the Prostate Cancer Section Head, GU Oncology, at Memorial Sloan Kettering Cancer Center in New York City. Dr. Morris is a Board-Certified medical oncologist who specializes in treating men with prostate cancer, especially those who have metastatic disease or are at high risk of developing metastatic disease. He received his MD from the Icahn School of Medicine at Mt. Sinai, completed a Residency at Columbia Presbyterian Medical Center, and completed a Fellowship in Oncology/Hematology at Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College. Dr. Morris has a special research interest in bone- and tumor-directed radiopharmaceuticals, and in developing novel imaging biomarkers for prostate cancer. He has written extensively on future directions of PSMA Imaging in prostate cancer and in the use of Theranostics to treat the disease. These represent new ways to not only manage prostate cancer but to stage it, as he tells us that many patients with non-metastatic CRPC patients may be metastatic when subjected to molecular imaging with PSMA-based imaging.